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Albuminuria and cardiovascular risk in hypertensive patients
with left ventricular hypertrophy: The LIFE Study. Studies have
shown that albuminuria is associated with increased risk for
cardiovascular events. We tested the relationship between al-
buminuria (UACR) and cardiovascular risk in 8206 hyperten-
sive patients with left ventricular hypertrophy included in the
LIFE Study. Follow-up was 39,122 patient years. The risk for the
primary composite cardiovascular end point increases continu-
ously from the lowest to the highest decile of baseline UACR.
No specific threshold could be identified. In conclusion, albu-
minuria predicts the outcome in the LIFE Study. The risk for
cardiovascular morbidity and mortality among hypertensive pa-
tients with left ventricular hypertrophy increases at much lower
UACR than has been reported in diabetic patients.
A number of studies have demonstrated that microal-
buminuria is an independent predictor of cardiovascular
disease and increased all-cause mortality also in subjects
with hypertension [1–3], although the evidence has been
scarce.
We showed that high albumin excretion rate was re-
lated to left ventricular hypertrophy (LVH), and was in-
dependent of age, blood pressure, diabetes, race, serum
creatinine, or smoking, suggesting parallel cardiac organ
damage and increased renal albumin excretion rate [4, 5],
most likely a marker of generalized hypertensive damage
to the peripheral vasculature [6].
We conducted a prospective study in a large group of
hypertensive patients with LVH to determine the albu-
minuria level at which cardiovascular morbidity and mor-
tality is increased.
METHODS
Eligible patients were men and women, aged 55 to
80 years, with hypertension and ECG-LVH enrolled in
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the LIFE Study. Inclusion criteria were mean trough-
sitting SBP 160 to 200 mm Hg and/or mean sitting DBP
95 to 115 mm Hg after two weeks of placebo treatment.
Important exclusion criteria were myocardial infarction
or stroke within six months, heart failure, or renal insuf-
ficiency (serum creatinine >160 mmol/L or 1.8 mg/dL).
Details on the LIFE Study population have been reported
elsewhere [7].
A morning spot urine sample was collected at base-
line, and repeated each year of follow-up. Urine albumin
concentration (mg/L) was expressed as a ratio to urinary
creatinine concentration (mmol/L).
This report is based on analyses of primary composite
end points (N = 971), which were defined as the first oc-
currence of cardiovascular death plus nonfatal myocar-
dial infarction, and nonfatal stoke. All-cause mortality
(N = 703) was a secondary end point. Further analyses
were made on cardiovascular death (N = 383), fatal and
nonfatal myocardial infarction (N = 344), and fatal and
nonfatal stroke (N = 479).
The patient population was divided according to
deciles of baseline urinary UACR. Clinical events were
analyzed using Cox proportional hazards models, and re-
ported hazard ratios (HR) are based on these models.
RESULTS
Patients (8206) had baseline measurements necessary
for inclusion in the present analyses. Patients were fol-
lowed for a median of 4.8 years and a total of 39,122
patient-years.
The relationship between deciles of baseline UACR
and end point rate are shown in Figures 1 to 4. For pri-
mary composite end point, cardiovascular mortality, all-
cause mortality, stroke, and myocardial infarction, there
is an approximate 3- to 5-fold increase in risk from the
lowest to the highest decile. Already at the median value
(UACR 1.28 mg/mmol), the risk is significantly increased
as compared to the risk seen in the lowest decile.
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Fig. 1. Composite end point rate according to deciles of urine albu-
min/creatinine. ∗Adjusted for ECG LV mass, Framingham Risk Score,
and study treatment allocation.
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Fig. 2. Cardiovascular mortality rate according to deciles of urine albu-
min/creatinine. ∗Adjusted for ECG LV mass, Framingham Risk Score,
and study treatment allocation.
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Fig. 3. All-cause mortality rate according to deciles of urine albu-
min/creatinine. ∗Adjusted for ECG LV mass, Framingham Risk Score,
and study treatment allocation.
For every 10-fold increase in UACR, the hazard ra-
tios of the end points increased as follows: composite end
point by 54.9% (CI 40.9-70.3); cardiovascular mortality
by 84.5% (CI 59.4-214); all-cause mortality by 66.4% (CI
48.9-86.0); stroke by 49.3% (CI 30.3-71.0); and myocar-
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Stroke rate
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Fig. 4. Fatal and nonfatal stroke rate according to deciles of urine albu-
min/creatinine. ∗Adjusted for ECG LV mass, Framingham Risk Score,
and study treatment allocation.
dial infarction by 41% (CI 20.1-65.5) (P < 0.001 for all
comparisons).
Data on nondiabetic patients (N = 7143) and diabetic
patients (N = 1063) have been reported earlier [3].
DISCUSSION
As UACR increased, risk for subsequent cardiovas-
cular events in hypertensive patients continuously in-
creased, and there appear to be no unique thresholds
at which increased albuminuria predicts cardiovascular
morbidity and mortality.
The risk for the composite cardiovascular end point
was increased already at a UACR partition value of
1.28 mg/mmol (the median value for the whole popula-
tion); for the nondiabetic patients the risk was increased
already at the median value UACR 1.16 mg/mmol [3].
The study shows the prognostic value of UACR at a level
far below the current definition of microalbuminuria.
Albuminuria assessment in hypertensive patient im-
proves cardiovascular risk stratification. The relationship
between left ventricular mass and UACR is documented
in patients with newly diagnosed hypertension, and those
with target organ damage [4, 5]. Detecting microalbu-
minuria might help the clinician decide when to initiate
antihypertensive therapy because identification of target
organ damage.
CONCLUSION
Increased UACR resulted in increasing risk of cardio-
vascular morbidity and mortality among hypertensive pa-
tients with LVH. We found no thresholds or plateaus. Risk
increases at much lower UACR values than has been re-
ported among diabetic patients.
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